Actinium Pharmaceuticals (ATNM) Accumulated Expenses (2010 - 2018)
Actinium Pharmaceuticals (ATNM) posted quarterly Accumulated Expenses of $15000.0 for Q3 2018, down 66.67% year-over-year from $45000.0 in Q3 2017, and down 66.67% quarter-over-quarter from $45000.0 in Q3 2017.
Actinium Pharmaceuticals (ATNM) Accumulated Expenses (2010 - 2018) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Accumulated Expenses for 5 consecutive years, with $15000.0 the latest figure, recorded in Q3 2018.
- In Q3 2018, Accumulated Expenses fell 66.67% year-over-year to $15000.0; the TTM figure through Sep 2018 stood at $15000.0 (down 66.67% YoY), while the FY2012 annual figure was $1090.0, down 95.61% from the prior year.
- Accumulated Expenses slipped to $15000.0 in Q3 2018 per ATNM's latest filing, from $45000.0 in the prior quarter.
- Across five years, Accumulated Expenses topped out at $45000.0 in Q3 2017 and bottomed at $15000.0 in Q3 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2018 | 15,000.00 |
| Sep 30, 2017 | 45,000.00 |
| Jun 30, 2017 | 44,000.00 |
| Sep 30, 2012 | 1,090.00 |
| Jun 30, 2012 | 550.00 |
| Mar 31, 2012 | 1,710.00 |
| Dec 31, 2011 | 26,005.00 |
| Sep 30, 2011 | 24,839.00 |
| Jun 30, 2011 | 810.00 |
| Dec 31, 2010 | 1,120.00 |